Screener
Aardvark Therapeutics, Inc. AARD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Aardvark Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Aardvark Therapeutics, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 9:32 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210675
FAQ
- What is Aardvark Therapeutics, Inc.'s EPS (diluted)?
- Aardvark Therapeutics, Inc. (AARD) reported EPS (diluted) of -$0.99 in Q1 2026.
- How has Aardvark Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Aardvark Therapeutics, Inc.'s EPS (diluted) decreased by 39.4% year-over-year, from -$0.71 to -$0.99.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Aardvark Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude